BioCorRx, Inc. Strengthens Product-Market Growth with New Contract
Addiction rehabilitation leader BioCorRx, Inc. (OTCQB: BICX), developer of the Start Fresh Program, has announced that it has entered an agreement with BioWyze LLC in a move to strengthen its product-market growth in its niche, a new company statement said.
BioWyze will be assisting BioCorRx, Inc. in product development and market penetration strategies starting on September 8, 2014. The company has extensive experience providing solutions to companies in the biotech, pharma, medical device and clinical research sectors.
Under the agreement, BioCorRx, Inc. will be working directly with BioWyze’s team of marketing veterans including Jeff Bagshaw, Richard Maloy, Tobin Geatz, Jeff Reiniche, Vicky Robinson, and Grace Granato.
“We look forward to this strategic relationship with the BioWyze team. BioCorRx can benefit greatly from their expertise with many well-respected corporations in a wide variety of fields and specialties,” BioCorRx, Inc. CEO Kent Emry said in the statement.
“BioCorRx is entering an exciting growth phase of its business, and we are honored to have been selected by the leadership team to support their strategic corporate goals. Initially, our efforts will focus on establishing scalable business processes while optimizing current business,” Jeff Bagshaw, BioWyze Managing Partner said of the partnership.
“Supporting our licensees' expansion within their served market is a priority and will be an important function moving forward, as will be the identification of other expansion verticals along with the development of technology solutions,” he added.
Bagshaw has over 25 years of experience in clinical development, sales, marketing and product commercializationin health care. His experience includes leadership roles at contract research company Inclinix, Inc., and Hoffman La Roche, Bristol Myers Squibb and Exact Sciences.
Maloy, a principal of the company, lends his 20 years of experience in brand management, sales and trading in pharmaceuticals to Biowyze. His most notable work as of late is the development of Warner Chilcott.
Geatz, another principal at BioWyze, is also a seasoned pharmaceutical and biotech leader. He was a Special General Partner at Aurora Funds II, and founder and chairman of the board of Pharmatech Solutions. He has been a CEO of five private companies, according to the press release. (Read more about the company’s principals here.)
BioCorRx, Inc. is one of the fastest growing companies in the substance abuse treatment sector.
The company is widely known for its Start Fresh Program, a two-tiered program that takes a different approach to addiction rehabilitation. The first phase of the program involves an outpatient medical procedure to embed a specially formulated, biodegradable naltrexone implant under the skin and fatty tissue in the lower abdominal area.
The second tier of the program involves a private, one-on-one coaching program to address the specific needs of the individual and to helphim or her plan for a life free from substance abuse.
According to its website, the company has a huge upside potential and has the ability to corner a “significant market share of the $22 billion annual alcohol treatment market” in the United States.
For more information on BioCorRx, Inc.’s Start Fresh Program, you may reach the company’s headquarters via phone: 714-462-4880, or email: info@BioCorRx.com.
Learn more about investment opportunities with BioCorRx, Inc. through its new investor relations website www.BICXcorp.com.
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.